URB597
![]() |
|
Names | |
---|---|
IUPAC name
[3-(3-carbamoylphenyl)phenyl] N-cyclohexylcarbamate
|
|
Identifiers | |
546141-08-6 ![]() |
|
ChEMBL | ChEMBL184238 ![]() |
ChemSpider | 1156960 ![]() |
4339 | |
Jmol 3D model | Interactive image |
MeSH | URB597 |
PubChem | 1383884 |
|
|
|
|
Properties | |
C20H22N2O3 | |
Molar mass | 338.4 g/mol |
Vapor pressure | {{{value}}} |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
|
![]() ![]() ![]() |
|
Infobox references | |
URB597 is a relatively selective inhibitor of the enzyme fatty acid amide hydrolase (FAAH).[1][2] FAAH is the primary degradatory enzyme for the endocannabinoid anandamide and, as such, inhibition of FAAH leads to an accumulation of anandamide in the CNS and periphery where it activates cannabinoid receptors. In pre-clinical laboratory tests researchers found URB597 increased the production of endocannabinoids resulting in measurable antidepressant and analgesic effects.[3]
URB597 is also known as KDS-4103. KDS-4103 is being developed by Kadmus Pharmaceuticals, Inc. for clinical trials in humans. Kadmus claims, on their website (linked below) that this class of compounds may have antidepressant, anti-anxiety, and pain-killing effects.
See also
References
<templatestyles src="Reflist/styles.css" />
Cite error: Invalid <references>
tag; parameter "group" is allowed only.
<references />
, or <references group="..." />
External links
- Kadmus Pharmaceuticals official website[dead link]
- Modulation of anxiety through blockade of anandamide hydrolysis in Nature
- New drug acts as marijuana in the brain at cannabis.net
- Pages with reference errors
- Articles without KEGG source
- Articles without UNII source
- Pages using collapsible list with both background and text-align in titlestyle
- Chemical articles using a fixed chemical formula
- Articles with dead external links from September 2011
- Antidepressants
- Benzamides
- Phenol ethers
- Carbamates
- Endocannabinoid reuptake inhibitors